Publication:
A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors

Simple item page
dc.contributor.authorİNANÇ, GÜZİDE NEVSUN
dc.contributor.authorsİNANÇ G. N., TERZİOĞLU M. E., Karabulut Y., Yilmaz Z., Tarhan E. F., Enecik M. E., ŞAHİN A., Küçük A., Ayan A., Özgen M., et al.
dc.date.accessioned2023-07-17T08:59:09Z
dc.date.available2023-07-17T08:59:09Z
dc.date.issued2023-01-01
dc.description.abstractBackground/aim: To describe the disease activity and retention rate in rheumatoid arthritis (RA) patients with inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or tumor necrosis factor inhibitors (TNFis) who were prescribed tocilizumab (TCZ) as first-line or second-line biologic treatment in real-world setting. Materials and methods: Data gathered from patients’ files was used in a multicenter and retrospective context. Retention rates and the Disease Activity Score in 28 joints with CRP (DAS28-CRP) were evaluated at time points. The relationship of drug efficacy with factors such as smoking, obesity, and previous use of TNFis was also examined. Results: One hundred and twenty-four patients with a median (IQR) RA duration of 3.7 (7.4) years were included. Mean (SD) age was 52.9 (12.9) and 75% of the patients were female. TCZ retention rates in the 6th and 12th months were 94.1% and 86.6%, respectively. In all patients, DAS28-CRP level decreased significantly from baseline to Months 3 and 6. There was an increase in patients with remission and/or low disease activity and a decrease in patients with high disease activity at Month 3 and Month 6 (p < 0.001 for both). Disease activity was similar between subgroups based on body mass index, smoking status, and previous use of TNFis at any time point. Regres-sion analysis showed that absence of concomitant corticosteroid treatment independently was associated with remission/LDA achieve-ment at Month 6 [OR = 0.31, 95% CI (0.14– 0.72), p = 0.006], and Month 12 [OR = 0.35, 95% CI (0.13–0.94), p = 0.037]. Overall, 25 mild adverse events were reported. Conclusion: TCZ was found to be effective and safe in RA patients with IR to csDMARDs and/or TNFis. The drug retention rate was considered satisfactory with more than half of the patients continuing TCZ treatment at Month 12.
dc.identifier.citationİNANÇ G. N., TERZİOĞLU M. E., Karabulut Y., Yilmaz Z., Tarhan E. F., Enecik M. E., ŞAHİN A., Küçük A., Ayan A., Özgen M., et al., "A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors", Turkish Journal of Medical Sciences, cilt.53, sa.3, ss.731-743, 2023
dc.identifier.doi10.55730/1300-0144.5636
dc.identifier.endpage743
dc.identifier.issn1300-0144
dc.identifier.issue3
dc.identifier.startpage731
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/eadf4147-7009-43e9-966c-542f2118f65f/file
dc.identifier.urihttps://hdl.handle.net/11424/291300
dc.identifier.volume53
dc.language.isoeng
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectFundamental Medical Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectMEDICINE, GENERAL & INTERNAL
dc.subjectGenel Tıp
dc.subjectGeneral Medicine
dc.subjectanti-interleukin-6
dc.subjectRheumatoid arthritis
dc.subjecttocilizumab
dc.titleA national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors
dc.typearticle
dspace.entity.typePublication
local.avesis.ideadf4147-7009-43e9-966c-542f2118f65f
local.indexed.atSCOPUS
relation.isAuthorOfPublicationc963a17b-4775-4dd7-8db7-ea072cc49ef1
relation.isAuthorOfPublication.latestForDiscoveryc963a17b-4775-4dd7-8db7-ea072cc49ef1

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2.pdf
Size:
787.84 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs